Inhibikase Therapeutics

NasdaqCM:IKT Stock Report

Mkt Cap: US$23.0m

Inhibikase Therapeutics Management

How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Milton Werner (59 yo)





Dr. Milton H. Werner, Ph D., serves as the Chief Executive Officer and President at Inhibikase Therapeutics, Inc. since June 2010. Prior to founding Inhibikase, From May 2007 until August 2008, Dr. Werner...

CEO Compensation Analysis

Milton Werner's Compensation vs Inhibikase Therapeutics Earnings
How has Milton Werner's remuneration changed compared to Inhibikase Therapeutics's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a


Mar 31 2022n/an/a


Dec 31 2021US$472kUS$455k


Sep 30 2021n/an/a


Jun 30 2021n/an/a


Mar 31 2021n/an/a


Dec 31 2020US$961kUS$293k


Sep 30 2020n/an/a


Jun 30 2020n/an/a


Mar 31 2020n/an/a


Dec 31 2019US$385kUS$293k


Sep 30 2019n/an/a


Mar 31 2019n/an/a


Dec 31 2018US$535kUS$452k


Compensation vs Market: Milton's total compensation ($USD472.11K) is below average for companies of similar size in the US market ($USD772.00K).

Compensation vs Earnings: Milton's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: IKT's management team is seasoned and experienced (7.9 years average tenure).

Board Members

Experienced Board: IKT's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.